Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Autoimmune Clear all
Completed Phase 4 Interventional Results available

Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept

NCT01875991
View directory record Official record
Conditions
Rheumatoid Arthritis, Plaque Psoriasis
Interventions
Etanercept via Autoinjector A, Etanercept via Autoinjector B
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
28
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Glendale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2018 · Synced Sep 7, 2026, 2:34 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

NCT06282159
View directory record Official record
Conditions
Myasthenia Gravis, Generalized
Interventions
Claseprubart, Placebo
Drug
Lead sponsor
Dianthus Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
21
States / cities
Phoenix, Arizona • Irvine, California • Stamford, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 7, 2026, 2:34 PM EDT
Recruiting Not applicable Interventional

Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients

NCT07392879
View directory record Official record
Conditions
Progressive Multiple Sclerosis, Depression
Interventions
Virtual Reality, Standard care
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 7, 2026, 2:34 PM EDT
Recruiting Phase 4 Interventional

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

NCT06072482
View directory record Official record
Conditions
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions
Avacopan, Placebo, Standard of Care
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
62
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Surprise, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 7, 2026, 2:34 PM EDT
Terminated Phase 1 Interventional

Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

NCT01164917
View directory record Official record
Conditions
Cutaneous Lupus, Discoid Lupus, Lupus, Systemic Lupus Erythematosus
Interventions
AMG811, AMG811 Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Santa Monica, California • Stanford, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Sep 7, 2026, 2:34 PM EDT
Completed No phase listed Observational Results available

Control-IQ Observational (CLIO) Post-Approval Study

NCT04503174
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
t:slim X2 pump with Control-IQ technology
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
6 Years and older
Enrollment
3,157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Sep 7, 2026, 2:34 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

NCT00768040
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Sep 7, 2026, 2:34 PM EDT
Completed No phase listed Observational

Belimumab (BENLYSTA®) Pregnancy Registry

NCT01532310
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
belimumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
2
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 7, 2026, 2:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

NCT01274182
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GP2013, MabThera, Rituxan
Biological
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
16
States / cities
Los Angeles, California • Lexington, Kentucky • Cumberland, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 7, 2026, 2:34 PM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

NCT07176390
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Tulisokibart, Placebo, Methotrexate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Glendale, Arizona • Mesa, Arizona • La Palma, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 7, 2026, 2:34 PM EDT
Terminated Phase 2 Interventional

Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis

NCT01268280
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Placebo, 250 mg CK-2017357, 500 mg CK-2017357
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
15
States / cities
Fresno, California • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Sep 7, 2026, 2:34 PM EDT
Not listed Phase 1 Interventional

Exercise for Stable Myasthenia Gravis

NCT01047761
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Exercise
Other
Lead sponsor
Baltimore VA Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Sep 7, 2026, 2:34 PM EDT
Completed No phase listed Observational

Cause, Development, and Progression of Stiff-Person Syndrome

NCT00030940
View directory record Official record
Conditions
Stiff-Person Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
25 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 7, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis

NCT00053417
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Placebo, 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP), 15 mg fampridine-SR (4-aminopyridine, 4-AP), 20 mg fampridine-SR (4-aminopyridine, 4-AP)
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Sep 7, 2026, 2:34 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

NCT00381810
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Rituximab, Methylprednisolone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
16 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
11
States / cities
Paradise Valley, Arizona • San Leandro, California • Boise, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 7, 2026, 2:34 PM EDT
Active, not recruiting No phase listed Observational

Novel Antineuronal Antibodies in Gastrointestinal Motility Disorders

NCT04872439
View directory record Official record
Conditions
Autoimmune Gastrointestinal Dysmotility
Interventions
Blood sample collection
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 7, 2026, 2:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterization of Childhood-Onset Obsessive-Compulsive Disorder

NCT00044239
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
4 Years to 12 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2010
U.S. locations
4
States / cities
Little Rock, Arkansas • Gainesville, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 7, 2026, 2:34 PM EDT
Not listed Phase 1 Interventional

Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis

NCT04559412
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sofusa DoseConnect, Enbrel
Device · Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 7, 2026, 2:34 PM EDT
Completed Phase 2 Interventional

Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis

NCT00141830
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate plus ERB-041 for 12 weeks, Placebo for 12 weeks
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
14
States / cities
Largo, Florida • Palm Harbor, Florida • Sarasota, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Sep 7, 2026, 2:34 PM EDT
Completed No phase listed Observational

Pregnancy Exposure Registry for Tysabri®

NCT00472992
View directory record Official record
Conditions
Crohn's Disease, Prenatal Exposure, Multiple Sclerosis, Pregnancy
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Sep 7, 2026, 2:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis

NCT00594932
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Arthritis
Interventions
mycophenolate mofetil, placebo
Drug · Other
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
14 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 7, 2026, 2:34 PM EDT
Withdrawn Phase 2 Interventional

A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders

NCT05974293
View directory record Official record
Conditions
NMO Spectrum Disorder, Spasticity, Muscle
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Michael, Levy M.D.,Ph.D.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 7, 2026, 2:34 PM EDT
Active, not recruiting No phase listed Observational

Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

NCT04598893
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Teplizumab, Placebo
Biological · Other
Lead sponsor
Provention Bio, a Sanofi Company
Industry
Eligibility
9 Years to 19 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
25
States / cities
San Diego, California • San Francisco, California • Walnut Creek, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 7, 2026, 2:34 PM EDT
Terminated Phase 2 Interventional Results available

Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus

NCT01709474
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Vitamin D3 6000 IU, Vitamin D3 400 IU
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 20 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Sep 7, 2026, 2:34 PM EDT